Fig. 2
From: Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
Progression free (a) and overall survival (b) among the study population (median duration of follow-up 139 days)
Fig. 2 | Journal for ImmunoTherapy of Cancer